Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa”), a special purpose acquisition company, announces it has entered into a business combination agreement with Silexion Ltd. (“Silexion”), a clinical-stage, oncology-focused biotechnology company, that would result in Silexion becoming publicly listed on the Nasdaq. The business combination provides for Silexion’s pre-transaction equity value to be $62.5 million, based on a $10 share price. Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene.
Read the full article: Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded via Business Combination with Moringa Acquisition Corp //
Source: https://www.globenewswire.com/news-release/2024/02/22/2833670/0/en/Silexion-a-Clinical-Stage-Oncology-Focused-Biotechnology-Company-to-Become-Publicly-Traded-Via-Business-Combination-with-Moringa-Acquisition-Corp.html